ROSANNA SAGELY: Open Payments
NPI 1295427417 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,013 in 52 payments from 14 companies in 2025. Trend: 2023 $356 · 2024 $936 · 2025 $1,013
Food & beverage: $1,013
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 8 | $178 |
| Amgen Inc. | 9 | $159 |
| Novo Nordisk Inc | 6 | $150 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 7 | $104 |
| Alnylam Pharmaceuticals Inc. | 4 | $77 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $74 |
| AstraZeneca Pharmaceuticals LP | 4 | $72 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Boston Scientific Corporation | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
Products named: REPATHA, VERQUVO, LifeVest, Wegovy, AMVUTTRA, Kerendia, WAINUA, NEXLETOL.
Industry payments across MS — which companies pay providers there.
